ArticleDigital health
LExNet: A bio-inspired lightweight ensemble model for breast cancer classification using hybrid autoencoder and swarm intelligence optimization.
Article in Digital health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Breast cancer (BC) remains a significant global health issue, with an estimated 2.3 million new cases and approximately 670,000 deaths recorded in 2022 alone. Accurate and timely diagnosis from histopathological images is critical yet challenging due to the manual and labour-intensive nature of conventional pathology assessments and high inter-observer variability. To address these challenges, this study introduces LExNet, a bio-inspired lightweight ensemble model that integrates hybrid autoencoder-based feature extraction and Particle Swarm Optimization (PSO) for hyperparameter tuning. Methods: The proposed model utilizes a robust ensemble of lightweight convolutional neural network (CNN) architectures, specifically MobileNetV3, EfficientNet-B0, ShuffleNet-V2, and SqueezeNet, to ensure computational efficiency and high accuracy. Results: Experimental evaluation of the ICIAR 2018 Breast Cancer Histology (BACH) dataset demonstrates that LExNet achieves a superior validation accuracy of approximately 98.3%, surpassing traditional deep-learning models by approximately 12% while reducing computational demands by 40-50%. The autoencoder-driven feature extraction significantly improved noise and dimensionality reduction, effectively decreasing overfitting risk by over 30%. Additionally, PSO-driven hyperparameter tuning notably accelerated convergence and reduced manual hyperparameter tuning time by up to 70%. Grad-CAM interpretability analysis further confirms that LExNet's predictions closely align with critical pathological features recognized by expert pathologists, highlighting its clinical relevance. Conclusion: Consequently, LExNet offers a robust, interpretable, and computationally efficient solution for real-time breast cancer diagnostics, making it particularly suitable for resource-constrained clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.